The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased aTyr Pharma Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR) common stock between January 16, 2025 and September 12, 2025, inclusive (the “Class Period”). aTyr investors have until December 8, 2025 to file a lead plaintiff motion.

IF YOU SUFFERED A LOSS ON YOUR ATYR PHARMA INC. (ATYR), INVESTMENTS, CLICK HERE TO SUBMIT A CLAIM TO POTENTIALLY RECOVER YOUR LOSSES IN THE ONGOING SECURITIES FRAUD LAWSUIT.

You can also contact the Law Offices of Frank R. Cruz to discuss your legal rights by email at info@frankcruzlaw.com, by telephone at (310) 914-5007, or visit our website at www.frankcruzlaw.com.

What Happened?

On September 15, 2025, aTyr announced that the Phase 3 study of its intravenous Efzofitimod pulmonary sarcoidosis treatment, EFZO-FIT, did not meet its primary endpoint in change from baseline in mean daily OCS dose at week 48.

On this news, aTyr’s stock price fell $5.01, or 83.2%, to close at $1.02 per share on September 15, 2025, thereby injuring investors.

What Is The Lawsuit About?

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Defendants created adverse facts concerning aTyr’s study design for EFZO-FIT, giving the false impression that Efzofitimod would meet its primary endpoint; (2) Defendants crafted a narrative that the Phase 3 EFZO-FIT study would provide a way for patients to fully remove steroids from their treatment plans; (3) there may be other factors that permit patients to completely remove steroids from their treatment plans; (4) thus, their Phase 3 EFZOFIT study failed to meet the primary endpoint in change from baseline in mean daily OCS dose at week 48; and (5) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Contact Us To Participate or Learn More:

If you purchased aTyr common stock, wish to learn more about this action, or have any questions concerning this announcement or your rights or interests with respect to these matters, please click HERE or contact us at:

Law Offices of Frank R. Cruz

2121 Avenue of the Stars, Suite 800

Telephone: 310-914-5007

Email: info@frankcruzlaw.com

Visit our website at: www.frankcruzlaw.com

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251017567669/en/

Law Offices of Frank R. Cruz Encourages aTyr Pharma Inc. (ATYR) Shareholders To Inquire About Securities Fraud Class Action